CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Clinical trial NCT02132624 · COMPLETED
Trial details
- NCT number
- NCT02132624
- Sponsor
- Uppsala University
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-04-01
- Primary completion
- 2017-05-31
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.